DXCMNASDAQ— DexCom Inc Price & Analysis

DexCom Inc

HEALTHCARE — MEDICAL DEVICES

$77.94

-$0.38-0.49%

Market Cap: $29.55B; Large Cap
P/E Ratio: 31.84; Fwd: 28.25
EPS (TTM): $2.46
Div. Yield: N/A

Technical Summary

RSI (14)32.06Neutral

SMA (50)$86.83Bearish

SMA (200)$74.31Bullish

MACD-1.5226Bearish

Bollinger$79.20 – $89.87Lower

Stochastic7.05Oversold

Theo Outlook

Dexcom develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. For the twelve months ended June 30, 2026, it reported revenue of $4.97 billion, a profit margin of 20.1 percent, earnings per share of $2.46, and a market capitalization of $29.55 billion.

Bull case: revenue grew 13.1 percent year over year in the latest quarter while earnings per share rose 43.6 percent and return on equity reached 38.5 percent. Bear case: operating margin stands at 24.3 percent and quarterly revenue growth slowed to 13.1 percent from prior periods.

The main risks include competition in medical devices and regulatory changes affecting diabetes products. Analysis generated by HeyTheo AI from company and market data. It may be incomplete or inaccurate.

Analysis generated by HeyTheo AI on Oct 23, 2026.

Company Overview

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

Fundamental Snapshot

Revenue: $4.97B
EBITDA: $1.40B
Gross Profit: $3.10B
Operating Margin: 24.3%
Profit Margin: 20.1%
ROE: 38.5%
Book Value: $6.95
Beta: 1.48
52-Wk High: $92.59
52-Wk Low: $54.11
Volume: 5.12M
PEG Ratio: 1.35

Frequently Asked Questions

What does Dexcom do?

Dexcom develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. It operates internationally with headquarters in San Diego, California.

Where does Dexcom's revenue come from?

Dexcom reported total revenue of $4.97 billion for the twelve months ended June 30, 2026. Revenue per share stood at $12.87 over the same period.

How does Dexcom compete?

Dexcom holds a profit margin of 20.1 percent and an operating margin of 24.3 percent as of June 30, 2026. Its return on assets was 10.3 percent and return on equity reached 38.5 percent over the trailing twelve months.

What are the main risks for Dexcom?

Dexcom faces risks from competition in the medical devices sector and potential regulatory changes. Its beta of 1.477 as of the latest data indicates above-average market volatility.

How is Dexcom valued?

Dexcom trades at a trailing price-to-earnings ratio of 31.84 and a forward price-to-earnings ratio of 28.25 as of the latest quarter ended June 30, 2026. Its price-to-sales ratio is 5.95 and price-to-book ratio is 12.63.